The quarter itself offers no clean earnings surprise. Q2 net loss was $33.4 million, or $0.95 per share, versus $42.4 million, or $1.47 per share, a year earlier; without a reliable published consensus, the result is best treated as in line rather than a substantiated beat. The year-over-year comparison is also imperfect because First Tracks separated from AnaptysBio on April 20, 2026 and prior-period expenses included combined-company allocations (Financial Results).
| Metric | Q2 2026 | Q2 2025 | Six months 2026 | Six months 2025 |
|---|---|---|---|---|
| Research and development expense | $25.6M | $39.3M | $59.6M | $80.7M |
| General and administrative expense | $9.3M | $6.6M | $28.1M | $16.4M |
| Net loss | $33.4M | $42.4M | $83.9M | $89.6M |
| Net loss per share | $0.95 | $1.47 | $2.40 | $3.02 |
| Cash, cash equivalents and investments | $168.0M | — | — | — |
The new information is operational, not clinical. FDA Fast Track designation for ANB033 in celiac disease is a modest positive because it can support more frequent regulatory interaction, but it does not establish efficacy or safety. The company also expanded Cohort 2 to as many as 40 patients across a broader range of disease severity, which may make the eventual readout more informative but also raises the importance of execution (Business Update).
The key timelines were maintained, not accelerated. Cohort 1 celiac data remain targeted for Q4 2026, Cohort 2 data for Q1 2027, and eosinophilic esophagitis data for Q3 2027. Those dates were already part of the standing development story, so the filing mostly confirms the calendar rather than creating a new near-term catalyst (ANB033 Clinical Update).
Funding remains adequate for the disclosed plan, but the balance sheet is not stronger than before the separation. Cash and investments fell from $311.6 million at December 31, 2025 to $168.0 million at June 30, 2026, while the company reaffirmed runway into Q2 2028, including two additional indications planned for the first half of 2027 (Balance Sheets; Business Update). The net read is mixed: modestly better development optionality from Fast Track and the larger cohort, offset by no clinical proof yet and a routine financial update.
Read the original 8-K on SEC EDGAR ↗